-$0.07 EPS Expected for AzurRx BioPharma, Inc. (NASDAQ:AZRX) This Quarter

Equities analysts expect that AzurRx BioPharma, Inc. (NASDAQ:AZRX) will report earnings of ($0.07) per share for the current quarter, according to Zacks. Zero analysts have made estimates for AzurRx BioPharma’s earnings. AzurRx BioPharma posted earnings of ($0.20) per share during the same quarter last year, which would suggest a positive year over year growth rate of 65%. The business is scheduled to report its next earnings results on Friday, June 25th.

On average, analysts expect that AzurRx BioPharma will report full year earnings of ($0.29) per share for the current year, with EPS estimates ranging from ($0.32) to ($0.23). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.31) per share, with EPS estimates ranging from ($0.32) to ($0.29). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow AzurRx BioPharma.

AzurRx BioPharma (NASDAQ:AZRX) last posted its quarterly earnings data on Sunday, May 23rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.07).

A number of equities analysts recently weighed in on AZRX shares. HC Wainwright restated a “buy” rating and set a $2.50 target price on shares of AzurRx BioPharma in a report on Wednesday, April 14th. Zacks Investment Research cut shares of AzurRx BioPharma from a “hold” rating to a “sell” rating in a research report on Wednesday, June 2nd. Maxim Group started coverage on shares of AzurRx BioPharma in a research report on Thursday, April 1st. They set a “buy” rating and a $3.00 price objective for the company. Finally, Roth Capital reduced their price objective on shares of AzurRx BioPharma from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, April 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. AzurRx BioPharma currently has a consensus rating of “Hold” and a consensus price target of $2.88.

AZRX traded up $0.03 during trading on Thursday, reaching $0.82. 527,295 shares of the stock were exchanged, compared to its average volume of 6,011,151. AzurRx BioPharma has a twelve month low of $0.65 and a twelve month high of $2.63. The business’s 50 day moving average price is $0.84.

A number of institutional investors and hedge funds have recently bought and sold shares of AZRX. Royal Bank of Canada acquired a new position in AzurRx BioPharma during the first quarter worth about $27,000. Newman Dignan & Sheerar Inc. acquired a new position in AzurRx BioPharma during the first quarter worth about $32,000. Jane Street Group LLC acquired a new position in AzurRx BioPharma during the first quarter worth about $74,000. Armistice Capital LLC acquired a new position in AzurRx BioPharma during the first quarter worth about $80,000. Finally, Virtu Financial LLC acquired a new position in AzurRx BioPharma during the first quarter worth about $104,000. 4.21% of the stock is owned by institutional investors and hedge funds.

About AzurRx BioPharma

AzurRx BioPharma, Inc, a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency.

See Also: How is net asset value different from market price?

Get a free copy of the Zacks research report on AzurRx BioPharma (AZRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AzurRx BioPharma (NASDAQ:AZRX)

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.